Cytek Biosciences will announce Q3 2025 financial results on November 5, followed by a conference call.
Quiver AI Summary
Cytek Biosciences, Inc. announced it will release its financial results for the third quarter of 2025 on November 5, 2025, after market close. A conference call to discuss the results and provide updates on business developments will be held at 1:30 p.m. PT / 4:30 p.m. ET, with a live webcast available on the company's investor website. Cytek is known for its innovative cell analysis tools that utilize patented Full Spectrum Profiling technology, enhancing the precision and sensitivity of cell analysis. The company's product line includes various flow cytometers and imaging systems, catering to research purposes and certain clinical applications. Cytek encourages investors to follow its financial announcements through its website and social media channels for updates and disclosures.
Potential Positives
- Cytek Biosciences will report its third quarter 2025 financial results on November 5, 2025, which is a significant upcoming event for stakeholders and investors.
- The company will host a webcast conference call after the earnings report to discuss business developments and outlook, providing transparency and engagement with investors.
- Cytek's focus on high-resolution and high-sensitivity cell analysis technologies through its patented Full Spectrum Profiling™ (FSP®) demonstrates its innovative approach and leadership in the cell analysis solutions market.
Potential Negatives
- The release does not provide any financial guidance or expectations for the upcoming quarter, which may lead to uncertainty among investors.
- The mention of products being for research use only could limit market potential and investor confidence in revenue generation.
FAQ
When will Cytek Biosciences report its financial results for Q3 2025?
Cytek Biosciences will report its Q3 2025 financial results after market close on November 5, 2025.
What time is the Cytek Biosciences webcast conference call?
The conference call will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 5, 2025.
Where can I listen to the Cytek Biosciences conference call?
Live audio of the conference call will be available on the 'Investors' section of Cytek's website.
What technologies does Cytek Biosciences specialize in?
Cytek specializes in high-resolution cell analysis tools using its patented Full Spectrum Profiling™ technology.
Where is Cytek Biosciences headquartered?
Cytek Biosciences is headquartered in Fremont, California, with offices and distribution channels worldwide.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CTKB Insider Trading Activity
$CTKB insiders have traded $CTKB stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CTKB stock by insiders over the last 6 months:
- WILLIAM D. MCCOMBE (Chief Financial Officer) purchased 35,000 shares for an estimated $97,300
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CTKB Hedge Fund Activity
We have seen 85 institutional investors add shares of $CTKB stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TOPLINE CAPITAL MANAGEMENT, LLC added 3,760,485 shares (+255.7%) to their portfolio in Q2 2025, for an estimated $12,785,649
- VANGUARD GROUP INC removed 1,856,870 shares (-19.3%) from their portfolio in Q2 2025, for an estimated $6,313,358
- BLACKROCK, INC. removed 1,033,747 shares (-5.7%) from their portfolio in Q2 2025, for an estimated $3,514,739
- CENTERBOOK PARTNERS LP removed 845,405 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,874,377
- ROYCE & ASSOCIATES LP added 823,987 shares (+145.6%) to their portfolio in Q2 2025, for an estimated $2,801,555
- DIMENSIONAL FUND ADVISORS LP added 600,997 shares (+21.1%) to their portfolio in Q2 2025, for an estimated $2,043,389
- AQR CAPITAL MANAGEMENT LLC added 585,116 shares (+89.6%) to their portfolio in Q2 2025, for an estimated $1,989,394
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CTKB Analyst Ratings
Wall Street analysts have issued reports on $CTKB in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Sell" rating on 05/12/2025
To track analyst ratings and price targets for $CTKB, check out Quiver Quantitative's $CTKB forecast page.
$CTKB Price Targets
Multiple analysts have issued price targets for $CTKB recently. We have seen 2 analysts offer price targets for $CTKB in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $7.0 on 05/28/2025
- Matthew Sykes from Goldman Sachs set a target price of $3.0 on 05/12/2025
Full Release
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP
®
) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis
®
and Guava
®
brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at
www.cytekbio.com
.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( www.cytekbio.com ), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
[email protected]
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
[email protected]
